Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study
Background and Aim In high or moderate risk populations, periodic surveillance of patients at risk of progression from gastric precursor lesions (PL) to gastric cancer (GC) is the most effective strategy for reducing the burden of GC. Incomplete type of intestinal metaplasia (IIM) may be considered...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2016-05, Vol.31 (5), p.953-958 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 958 |
|---|---|
| container_issue | 5 |
| container_start_page | 953 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 31 |
| creator | González, Carlos A. Sanz-Anquela, José Miguel Companioni, Osmel Bonet, Catalina Berdasco, María López, Consuelo Mendoza, Jorge Martín-Arranz, Mª Dolores Rey, Enrique Poves, Elvira Espinosa, Laura Barrio, Jesús Torres, Mª Ángeles Cuatrecasas, Miriam Elizalde, Ignasi Bujanda, Luis Garmendia, Maddi Ferrández, Ángel Muñoz, Guillermo Andreu, Victoria Paules, Mª Jose Lario, Sergio Ramírez, Mª Jose Gisbert, Javier P. |
| description | Background and Aim
In high or moderate risk populations, periodic surveillance of patients at risk of progression from gastric precursor lesions (PL) to gastric cancer (GC) is the most effective strategy for reducing the burden of GC. Incomplete type of intestinal metaplasia (IIM) may be considered as the best candidate, but it is still controversial and more research is needed. To further assess the progression of subtypes of IM as predictors of GC occurrence.
Methods
A follow‐up study was carried‐out including 649 patients, diagnosed with PL between 1995–2004 in 9 participating hospitals from Spain, and who repeated the biopsy during 2011–2013. Medical information and habits were collected through a questionnaire. Based on morphology, IM was sub‐classified as complete (small intestinal type, CIM) and incomplete (colonic type, IIM). Analyses were done using Cox (HR) models.
Results
At baseline, 24% of patients had atrophic gastritis, 38% CIM, 34% IIM, and 4% dysplasia. Mean follow‐up was 12 years. 24 patients (3.7%) developed a gastric adenocarcinoma during follow‐up. The incidence rate of GC was 2.76 and 5.76 per 1,000 person‐years for those with CIM and IIM, respectively. The HR of progression to CG was 2.75 (95% CI 1.06‐6.26) for those with IIM compared with those with CIM at baseline, after adjusting for sex, age, smoking, family history of GC and use of NSAIDs.
Conclusions
IIM is the PL with highest risk to progress to GC. Sub‐typing of IM is a valid procedure for the identification of high risk patients that require more intensive surveillance. |
| doi_str_mv | 10.1111/jgh.13249 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785740140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1785740140</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4299-b172b4cce7ae7fdbfe684ac9a6bbf905ab59446768ccffd802189d9d5a70e8d03</originalsourceid><addsrcrecordid>eNp1kM1O3TAQha2qqFxoF32Byst2EbATJ7a7K7S9gBBVVSqWluNMbgzOT21HcJ-ir1ynF9gxG4883zljH4TeU3JEUx3fbrojWuRMvkIryhjJKGfVa7QigpaZLKjcRwch3BJCGOHlG7SfV1VBCkpW6O_5YMZ-chABx-0EeGyxHSKEaAftcA9RT04Hq3GnA44d4M5uujTG3oY7HEc8-XHjIYSl3-gQvTXY6MGA_4zT_exiWEwX6a9JDzZ0uB2dG--zecJ9GlsDaaHHIc7N9i3aa7UL8O7xPES_v3-7Pj3LLn-sz0-_XGaG5VJmNeV5zYwBroG3Td1CJZg2Uld13UpS6rqUjFW8Esa0bSNIToVsZFNqTkA0pDhEH3e-6fl_5vQf1dtgwDk9wDgHRbkoOSOULeinHWr8GIKHVk3e9tpvFSVqyV-l_NX__BP74dF2rntonsmnwBNwvAPurYPty07qYn32ZJntFDZEeHhWaH-nKl7wUt1crdXNzxORX8uvShT_AN7MoiI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1785740140</pqid></control><display><type>article</type><title>Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>González, Carlos A. ; Sanz-Anquela, José Miguel ; Companioni, Osmel ; Bonet, Catalina ; Berdasco, María ; López, Consuelo ; Mendoza, Jorge ; Martín-Arranz, Mª Dolores ; Rey, Enrique ; Poves, Elvira ; Espinosa, Laura ; Barrio, Jesús ; Torres, Mª Ángeles ; Cuatrecasas, Miriam ; Elizalde, Ignasi ; Bujanda, Luis ; Garmendia, Maddi ; Ferrández, Ángel ; Muñoz, Guillermo ; Andreu, Victoria ; Paules, Mª Jose ; Lario, Sergio ; Ramírez, Mª Jose ; Gisbert, Javier P.</creator><creatorcontrib>González, Carlos A. ; Sanz-Anquela, José Miguel ; Companioni, Osmel ; Bonet, Catalina ; Berdasco, María ; López, Consuelo ; Mendoza, Jorge ; Martín-Arranz, Mª Dolores ; Rey, Enrique ; Poves, Elvira ; Espinosa, Laura ; Barrio, Jesús ; Torres, Mª Ángeles ; Cuatrecasas, Miriam ; Elizalde, Ignasi ; Bujanda, Luis ; Garmendia, Maddi ; Ferrández, Ángel ; Muñoz, Guillermo ; Andreu, Victoria ; Paules, Mª Jose ; Lario, Sergio ; Ramírez, Mª Jose ; Gisbert, Javier P. ; Study group</creatorcontrib><description>Background and Aim
In high or moderate risk populations, periodic surveillance of patients at risk of progression from gastric precursor lesions (PL) to gastric cancer (GC) is the most effective strategy for reducing the burden of GC. Incomplete type of intestinal metaplasia (IIM) may be considered as the best candidate, but it is still controversial and more research is needed. To further assess the progression of subtypes of IM as predictors of GC occurrence.
Methods
A follow‐up study was carried‐out including 649 patients, diagnosed with PL between 1995–2004 in 9 participating hospitals from Spain, and who repeated the biopsy during 2011–2013. Medical information and habits were collected through a questionnaire. Based on morphology, IM was sub‐classified as complete (small intestinal type, CIM) and incomplete (colonic type, IIM). Analyses were done using Cox (HR) models.
Results
At baseline, 24% of patients had atrophic gastritis, 38% CIM, 34% IIM, and 4% dysplasia. Mean follow‐up was 12 years. 24 patients (3.7%) developed a gastric adenocarcinoma during follow‐up. The incidence rate of GC was 2.76 and 5.76 per 1,000 person‐years for those with CIM and IIM, respectively. The HR of progression to CG was 2.75 (95% CI 1.06‐6.26) for those with IIM compared with those with CIM at baseline, after adjusting for sex, age, smoking, family history of GC and use of NSAIDs.
Conclusions
IIM is the PL with highest risk to progress to GC. Sub‐typing of IM is a valid procedure for the identification of high risk patients that require more intensive surveillance.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.13249</identifier><identifier>PMID: 26630310</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Adenocarcinoma - epidemiology ; Adenocarcinoma - pathology ; Adult ; Biopsy ; Cell Transformation, Neoplastic - pathology ; Disease Progression ; Female ; Follow-Up Studies ; follow-up study ; gastric cancer risk ; Gastritis, Atrophic - epidemiology ; Gastritis, Atrophic - pathology ; Humans ; intestinal metaplasia ; Longitudinal Studies ; Male ; Metaplasia ; Middle Aged ; Multivariate Analysis ; Precancerous Conditions - epidemiology ; Precancerous Conditions - pathology ; Proportional Hazards Models ; Risk Assessment ; Risk Factors ; Spain - epidemiology ; Stomach - pathology ; Stomach Neoplasms - epidemiology ; Stomach Neoplasms - pathology ; Surveys and Questionnaires ; Time Factors</subject><ispartof>Journal of gastroenterology and hepatology, 2016-05, Vol.31 (5), p.953-958</ispartof><rights>2015 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd</rights><rights>2015 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4299-b172b4cce7ae7fdbfe684ac9a6bbf905ab59446768ccffd802189d9d5a70e8d03</citedby><cites>FETCH-LOGICAL-c4299-b172b4cce7ae7fdbfe684ac9a6bbf905ab59446768ccffd802189d9d5a70e8d03</cites><orcidid>0000-0003-2090-3445</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.13249$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.13249$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26630310$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>González, Carlos A.</creatorcontrib><creatorcontrib>Sanz-Anquela, José Miguel</creatorcontrib><creatorcontrib>Companioni, Osmel</creatorcontrib><creatorcontrib>Bonet, Catalina</creatorcontrib><creatorcontrib>Berdasco, María</creatorcontrib><creatorcontrib>López, Consuelo</creatorcontrib><creatorcontrib>Mendoza, Jorge</creatorcontrib><creatorcontrib>Martín-Arranz, Mª Dolores</creatorcontrib><creatorcontrib>Rey, Enrique</creatorcontrib><creatorcontrib>Poves, Elvira</creatorcontrib><creatorcontrib>Espinosa, Laura</creatorcontrib><creatorcontrib>Barrio, Jesús</creatorcontrib><creatorcontrib>Torres, Mª Ángeles</creatorcontrib><creatorcontrib>Cuatrecasas, Miriam</creatorcontrib><creatorcontrib>Elizalde, Ignasi</creatorcontrib><creatorcontrib>Bujanda, Luis</creatorcontrib><creatorcontrib>Garmendia, Maddi</creatorcontrib><creatorcontrib>Ferrández, Ángel</creatorcontrib><creatorcontrib>Muñoz, Guillermo</creatorcontrib><creatorcontrib>Andreu, Victoria</creatorcontrib><creatorcontrib>Paules, Mª Jose</creatorcontrib><creatorcontrib>Lario, Sergio</creatorcontrib><creatorcontrib>Ramírez, Mª Jose</creatorcontrib><creatorcontrib>Gisbert, Javier P.</creatorcontrib><creatorcontrib>Study group</creatorcontrib><title>Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study</title><title>Journal of gastroenterology and hepatology</title><addtitle>Journal of Gastroenterology and Hepatology</addtitle><description>Background and Aim
In high or moderate risk populations, periodic surveillance of patients at risk of progression from gastric precursor lesions (PL) to gastric cancer (GC) is the most effective strategy for reducing the burden of GC. Incomplete type of intestinal metaplasia (IIM) may be considered as the best candidate, but it is still controversial and more research is needed. To further assess the progression of subtypes of IM as predictors of GC occurrence.
Methods
A follow‐up study was carried‐out including 649 patients, diagnosed with PL between 1995–2004 in 9 participating hospitals from Spain, and who repeated the biopsy during 2011–2013. Medical information and habits were collected through a questionnaire. Based on morphology, IM was sub‐classified as complete (small intestinal type, CIM) and incomplete (colonic type, IIM). Analyses were done using Cox (HR) models.
Results
At baseline, 24% of patients had atrophic gastritis, 38% CIM, 34% IIM, and 4% dysplasia. Mean follow‐up was 12 years. 24 patients (3.7%) developed a gastric adenocarcinoma during follow‐up. The incidence rate of GC was 2.76 and 5.76 per 1,000 person‐years for those with CIM and IIM, respectively. The HR of progression to CG was 2.75 (95% CI 1.06‐6.26) for those with IIM compared with those with CIM at baseline, after adjusting for sex, age, smoking, family history of GC and use of NSAIDs.
Conclusions
IIM is the PL with highest risk to progress to GC. Sub‐typing of IM is a valid procedure for the identification of high risk patients that require more intensive surveillance.</description><subject>Adenocarcinoma - epidemiology</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Biopsy</subject><subject>Cell Transformation, Neoplastic - pathology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>follow-up study</subject><subject>gastric cancer risk</subject><subject>Gastritis, Atrophic - epidemiology</subject><subject>Gastritis, Atrophic - pathology</subject><subject>Humans</subject><subject>intestinal metaplasia</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Metaplasia</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Precancerous Conditions - epidemiology</subject><subject>Precancerous Conditions - pathology</subject><subject>Proportional Hazards Models</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Spain - epidemiology</subject><subject>Stomach - pathology</subject><subject>Stomach Neoplasms - epidemiology</subject><subject>Stomach Neoplasms - pathology</subject><subject>Surveys and Questionnaires</subject><subject>Time Factors</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1O3TAQha2qqFxoF32Byst2EbATJ7a7K7S9gBBVVSqWluNMbgzOT21HcJ-ir1ynF9gxG4883zljH4TeU3JEUx3fbrojWuRMvkIryhjJKGfVa7QigpaZLKjcRwch3BJCGOHlG7SfV1VBCkpW6O_5YMZ-chABx-0EeGyxHSKEaAftcA9RT04Hq3GnA44d4M5uujTG3oY7HEc8-XHjIYSl3-gQvTXY6MGA_4zT_exiWEwX6a9JDzZ0uB2dG--zecJ9GlsDaaHHIc7N9i3aa7UL8O7xPES_v3-7Pj3LLn-sz0-_XGaG5VJmNeV5zYwBroG3Td1CJZg2Uld13UpS6rqUjFW8Esa0bSNIToVsZFNqTkA0pDhEH3e-6fl_5vQf1dtgwDk9wDgHRbkoOSOULeinHWr8GIKHVk3e9tpvFSVqyV-l_NX__BP74dF2rntonsmnwBNwvAPurYPty07qYn32ZJntFDZEeHhWaH-nKl7wUt1crdXNzxORX8uvShT_AN7MoiI</recordid><startdate>201605</startdate><enddate>201605</enddate><creator>González, Carlos A.</creator><creator>Sanz-Anquela, José Miguel</creator><creator>Companioni, Osmel</creator><creator>Bonet, Catalina</creator><creator>Berdasco, María</creator><creator>López, Consuelo</creator><creator>Mendoza, Jorge</creator><creator>Martín-Arranz, Mª Dolores</creator><creator>Rey, Enrique</creator><creator>Poves, Elvira</creator><creator>Espinosa, Laura</creator><creator>Barrio, Jesús</creator><creator>Torres, Mª Ángeles</creator><creator>Cuatrecasas, Miriam</creator><creator>Elizalde, Ignasi</creator><creator>Bujanda, Luis</creator><creator>Garmendia, Maddi</creator><creator>Ferrández, Ángel</creator><creator>Muñoz, Guillermo</creator><creator>Andreu, Victoria</creator><creator>Paules, Mª Jose</creator><creator>Lario, Sergio</creator><creator>Ramírez, Mª Jose</creator><creator>Gisbert, Javier P.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2090-3445</orcidid></search><sort><creationdate>201605</creationdate><title>Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study</title><author>González, Carlos A. ; Sanz-Anquela, José Miguel ; Companioni, Osmel ; Bonet, Catalina ; Berdasco, María ; López, Consuelo ; Mendoza, Jorge ; Martín-Arranz, Mª Dolores ; Rey, Enrique ; Poves, Elvira ; Espinosa, Laura ; Barrio, Jesús ; Torres, Mª Ángeles ; Cuatrecasas, Miriam ; Elizalde, Ignasi ; Bujanda, Luis ; Garmendia, Maddi ; Ferrández, Ángel ; Muñoz, Guillermo ; Andreu, Victoria ; Paules, Mª Jose ; Lario, Sergio ; Ramírez, Mª Jose ; Gisbert, Javier P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4299-b172b4cce7ae7fdbfe684ac9a6bbf905ab59446768ccffd802189d9d5a70e8d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adenocarcinoma - epidemiology</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Biopsy</topic><topic>Cell Transformation, Neoplastic - pathology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>follow-up study</topic><topic>gastric cancer risk</topic><topic>Gastritis, Atrophic - epidemiology</topic><topic>Gastritis, Atrophic - pathology</topic><topic>Humans</topic><topic>intestinal metaplasia</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Metaplasia</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Precancerous Conditions - epidemiology</topic><topic>Precancerous Conditions - pathology</topic><topic>Proportional Hazards Models</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Spain - epidemiology</topic><topic>Stomach - pathology</topic><topic>Stomach Neoplasms - epidemiology</topic><topic>Stomach Neoplasms - pathology</topic><topic>Surveys and Questionnaires</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>González, Carlos A.</creatorcontrib><creatorcontrib>Sanz-Anquela, José Miguel</creatorcontrib><creatorcontrib>Companioni, Osmel</creatorcontrib><creatorcontrib>Bonet, Catalina</creatorcontrib><creatorcontrib>Berdasco, María</creatorcontrib><creatorcontrib>López, Consuelo</creatorcontrib><creatorcontrib>Mendoza, Jorge</creatorcontrib><creatorcontrib>Martín-Arranz, Mª Dolores</creatorcontrib><creatorcontrib>Rey, Enrique</creatorcontrib><creatorcontrib>Poves, Elvira</creatorcontrib><creatorcontrib>Espinosa, Laura</creatorcontrib><creatorcontrib>Barrio, Jesús</creatorcontrib><creatorcontrib>Torres, Mª Ángeles</creatorcontrib><creatorcontrib>Cuatrecasas, Miriam</creatorcontrib><creatorcontrib>Elizalde, Ignasi</creatorcontrib><creatorcontrib>Bujanda, Luis</creatorcontrib><creatorcontrib>Garmendia, Maddi</creatorcontrib><creatorcontrib>Ferrández, Ángel</creatorcontrib><creatorcontrib>Muñoz, Guillermo</creatorcontrib><creatorcontrib>Andreu, Victoria</creatorcontrib><creatorcontrib>Paules, Mª Jose</creatorcontrib><creatorcontrib>Lario, Sergio</creatorcontrib><creatorcontrib>Ramírez, Mª Jose</creatorcontrib><creatorcontrib>Gisbert, Javier P.</creatorcontrib><creatorcontrib>Study group</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>González, Carlos A.</au><au>Sanz-Anquela, José Miguel</au><au>Companioni, Osmel</au><au>Bonet, Catalina</au><au>Berdasco, María</au><au>López, Consuelo</au><au>Mendoza, Jorge</au><au>Martín-Arranz, Mª Dolores</au><au>Rey, Enrique</au><au>Poves, Elvira</au><au>Espinosa, Laura</au><au>Barrio, Jesús</au><au>Torres, Mª Ángeles</au><au>Cuatrecasas, Miriam</au><au>Elizalde, Ignasi</au><au>Bujanda, Luis</au><au>Garmendia, Maddi</au><au>Ferrández, Ángel</au><au>Muñoz, Guillermo</au><au>Andreu, Victoria</au><au>Paules, Mª Jose</au><au>Lario, Sergio</au><au>Ramírez, Mª Jose</au><au>Gisbert, Javier P.</au><aucorp>Study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>Journal of Gastroenterology and Hepatology</addtitle><date>2016-05</date><risdate>2016</risdate><volume>31</volume><issue>5</issue><spage>953</spage><epage>958</epage><pages>953-958</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aim
In high or moderate risk populations, periodic surveillance of patients at risk of progression from gastric precursor lesions (PL) to gastric cancer (GC) is the most effective strategy for reducing the burden of GC. Incomplete type of intestinal metaplasia (IIM) may be considered as the best candidate, but it is still controversial and more research is needed. To further assess the progression of subtypes of IM as predictors of GC occurrence.
Methods
A follow‐up study was carried‐out including 649 patients, diagnosed with PL between 1995–2004 in 9 participating hospitals from Spain, and who repeated the biopsy during 2011–2013. Medical information and habits were collected through a questionnaire. Based on morphology, IM was sub‐classified as complete (small intestinal type, CIM) and incomplete (colonic type, IIM). Analyses were done using Cox (HR) models.
Results
At baseline, 24% of patients had atrophic gastritis, 38% CIM, 34% IIM, and 4% dysplasia. Mean follow‐up was 12 years. 24 patients (3.7%) developed a gastric adenocarcinoma during follow‐up. The incidence rate of GC was 2.76 and 5.76 per 1,000 person‐years for those with CIM and IIM, respectively. The HR of progression to CG was 2.75 (95% CI 1.06‐6.26) for those with IIM compared with those with CIM at baseline, after adjusting for sex, age, smoking, family history of GC and use of NSAIDs.
Conclusions
IIM is the PL with highest risk to progress to GC. Sub‐typing of IM is a valid procedure for the identification of high risk patients that require more intensive surveillance.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>26630310</pmid><doi>10.1111/jgh.13249</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-2090-3445</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2016-05, Vol.31 (5), p.953-958 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1785740140 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adenocarcinoma - epidemiology Adenocarcinoma - pathology Adult Biopsy Cell Transformation, Neoplastic - pathology Disease Progression Female Follow-Up Studies follow-up study gastric cancer risk Gastritis, Atrophic - epidemiology Gastritis, Atrophic - pathology Humans intestinal metaplasia Longitudinal Studies Male Metaplasia Middle Aged Multivariate Analysis Precancerous Conditions - epidemiology Precancerous Conditions - pathology Proportional Hazards Models Risk Assessment Risk Factors Spain - epidemiology Stomach - pathology Stomach Neoplasms - epidemiology Stomach Neoplasms - pathology Surveys and Questionnaires Time Factors |
| title | Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T18%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Incomplete%20type%20of%20intestinal%20metaplasia%20has%20the%20highest%20risk%20to%20progress%20to%20gastric%20cancer:%20results%20of%20the%20Spanish%20follow-up%20multicenter%20study&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Gonz%C3%A1lez,%20Carlos%20A.&rft.aucorp=Study%20group&rft.date=2016-05&rft.volume=31&rft.issue=5&rft.spage=953&rft.epage=958&rft.pages=953-958&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.13249&rft_dat=%3Cproquest_cross%3E1785740140%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1785740140&rft_id=info:pmid/26630310&rfr_iscdi=true |